United States Orphan Drugs Market Report 2017

November 2017 | 107 pages | ID: UBC64A69A66WEN
QYResearch

Abstracts

In this report, the United States Orphan Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Orphan Drugs in these regions, from 2012 to 2022 (forecast).

United States Orphan Drugs market competition by top manufacturers/players, with Orphan Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Novartis AG
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Sanofi S.A.
• Alexion Pharmaceuticals, Inc.
• Eli Lilly and Company
• Novo Nordisk A/S
• AstraZeneca
• Eisai Co., Ltd.
• Daiichi Sankyo Company Limited
• Bayer AG
• GlaxoSmithKline
• Merck & Co., Inc.
• Johnson & Johnson
• Biogen, Inc.
• Shire
• Amgen, Inc.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Oncology
• Gastrointestinal
• Pulmonary
• Neurology
• Hematology
• Cardio-vascular
• Metabolic disorders
• Endocrinology
• Infectious diseases
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Orphan Drugs for each application, including

• Hospital Pharmacies
• Speciality Pharmacies
• Retail pharmacies
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Orphan Drugs Market Report 2017

1 ORPHAN DRUGS OVERVIEW

1.1 Product Overview and Scope of Orphan Drugs
1.2 Classification of Orphan Drugs by Product Category
  1.2.1 United States Orphan Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Orphan Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Oncology
  1.2.4 Gastrointestinal
  1.2.5 Pulmonary
  1.2.6 Neurology
  1.2.7 Hematology
  1.2.8 Cardio-vascular
  1.2.9 Metabolic disorders
  1.2.10 Endocrinology
  1.2.11 Infectious diseases
  1.2.12 Others
1.3 United States Orphan Drugs Market by Application/End Users
  1.3.1 United States Orphan Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospital Pharmacies
  1.3.3 Speciality Pharmacies
  1.3.4 Retail pharmacies
  1.3.5 Others
1.4 United States Orphan Drugs Market by Region
  1.4.1 United States Orphan Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Orphan Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Orphan Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Orphan Drugs Status and Prospect (2012-2022)
  1.4.5 New England Orphan Drugs Status and Prospect (2012-2022)
  1.4.6 The South Orphan Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Orphan Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Orphan Drugs (2012-2022)
  1.5.1 United States Orphan Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Orphan Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES ORPHAN DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Orphan Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Orphan Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Orphan Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Orphan Drugs Market Competitive Situation and Trends
  2.4.1 United States Orphan Drugs Market Concentration Rate
  2.4.2 United States Orphan Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Orphan Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES ORPHAN DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Orphan Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Orphan Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Orphan Drugs Price by Region (2012-2017)

4 UNITED STATES ORPHAN DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Orphan Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Orphan Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Orphan Drugs Price by Type (2012-2017)
4.4 United States Orphan Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES ORPHAN DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Orphan Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Orphan Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES ORPHAN DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Novartis AG
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Orphan Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Novartis AG Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Bristol-Myers Squibb Company
  6.2.2 Orphan Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Bristol-Myers Squibb Company Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Celgene Corporation
  6.3.2 Orphan Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Celgene Corporation Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 F. Hoffmann-La Roche Ltd.
  6.4.2 Orphan Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 F. Hoffmann-La Roche Ltd. Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Pfizer, Inc.
  6.5.2 Orphan Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Pfizer, Inc. Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Sanofi S.A.
  6.6.2 Orphan Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Sanofi S.A. Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Alexion Pharmaceuticals, Inc.
  6.7.2 Orphan Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Alexion Pharmaceuticals, Inc. Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Eli Lilly and Company
  6.8.2 Orphan Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Eli Lilly and Company Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Novo Nordisk A/S
  6.9.2 Orphan Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Novo Nordisk A/S Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 AstraZeneca
  6.10.2 Orphan Drugs Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 AstraZeneca Orphan Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Eisai Co., Ltd.
6.12 Daiichi Sankyo Company Limited
6.13 Bayer AG
6.14 GlaxoSmithKline
6.15 Merck & Co., Inc.
6.16 Johnson & Johnson
6.17 Biogen, Inc.
6.18 Shire
6.19 Amgen, Inc.

7 ORPHAN DRUGS MANUFACTURING COST ANALYSIS

7.1 Orphan Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Orphan Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Orphan Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Orphan Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES ORPHAN DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Orphan Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Orphan Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Orphan Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Orphan Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Orphan Drugs
Figure United States Orphan Drugs Market Size (K Units) by Type (2012-2022)
Figure United States Orphan Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Oncology Product Picture
Figure Gastrointestinal Product Picture
Figure Pulmonary Product Picture
Figure Neurology Product Picture
Figure Hematology Product Picture
Figure Cardio-vascular Product Picture
Figure Metabolic disorders Product Picture
Figure Endocrinology Product Picture
Figure Infectious diseases Product Picture
Figure Others Product Picture
Figure United States Orphan Drugs Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Orphan Drugs by Application in 2016
Figure Hospital Pharmacies Examples
Table Key Downstream Customer in Hospital Pharmacies
Figure Speciality Pharmacies Examples
Table Key Downstream Customer in Speciality Pharmacies
Figure Retail pharmacies Examples
Table Key Downstream Customer in Retail pharmacies
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Orphan Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Orphan Drugs Sales (K Units) and Growth Rate (2012-2022)
Figure United States Orphan Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Orphan Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Orphan Drugs Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Orphan Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Orphan Drugs Sales Share by Players/Suppliers
Figure 2017 United States Orphan Drugs Sales Share by Players/Suppliers
Figure United States Orphan Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Orphan Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Orphan Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Orphan Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Orphan Drugs Revenue Share by Players/Suppliers
Table United States Market Orphan Drugs Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Orphan Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Orphan Drugs Market Share of Top 3 Players/Suppliers
Figure United States Orphan Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Orphan Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Orphan Drugs Product Category
Table United States Orphan Drugs Sales (K Units) by Region (2012-2017)
Table United States Orphan Drugs Sales Share by Region (2012-2017)
Figure United States Orphan Drugs Sales Share by Region (2012-2017)
Figure United States Orphan Drugs Sales Market Share by Region in 2016
Table United States Orphan Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Orphan Drugs Revenue Share by Region (2012-2017)
Figure United States Orphan Drugs Revenue Market Share by Region (2012-2017)
Figure United States Orphan Drugs Revenue Market Share by Region in 2016
Table United States Orphan Drugs Price (USD/Unit) by Region (2012-2017)
Table United States Orphan Drugs Sales (K Units) by Type (2012-2017)
Table United States Orphan Drugs Sales Share by Type (2012-2017)
Figure United States Orphan Drugs Sales Share by Type (2012-2017)
Figure United States Orphan Drugs Sales Market Share by Type in 2016
Table United States Orphan Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Orphan Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Orphan Drugs by Type (2012-2017)
Figure Revenue Market Share of Orphan Drugs by Type in 2016
Table United States Orphan Drugs Price (USD/Unit) by Types (2012-2017)
Figure United States Orphan Drugs Sales Growth Rate by Type (2012-2017)
Table United States Orphan Drugs Sales (K Units) by Application (2012-2017)
Table United States Orphan Drugs Sales Market Share by Application (2012-2017)
Figure United States Orphan Drugs Sales Market Share by Application (2012-2017)
Figure United States Orphan Drugs Sales Market Share by Application in 2016
Table United States Orphan Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Orphan Drugs Sales Growth Rate by Application (2012-2017)
Table Novartis AG Basic Information List
Table Novartis AG Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis AG Orphan Drugs Sales Growth Rate (2012-2017)
Figure Novartis AG Orphan Drugs Sales Market Share in United States (2012-2017)
Figure Novartis AG Orphan Drugs Revenue Market Share in United States (2012-2017)
Table Bristol-Myers Squibb Company Basic Information List
Table Bristol-Myers Squibb Company Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Company Orphan Drugs Sales Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Company Orphan Drugs Sales Market Share in United States (2012-2017)
Figure Bristol-Myers Squibb Company Orphan Drugs Revenue Market Share in United States (2012-2017)
Table Celgene Corporation Basic Information List
Table Celgene Corporation Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Celgene Corporation Orphan Drugs Sales Growth Rate (2012-2017)
Figure Celgene Corporation Orphan Drugs Sales Market Share in United States (2012-2017)
Figure Celgene Corporation Orphan Drugs Revenue Market Share in United States (2012-2017)
Table F. Hoffmann-La Roche Ltd. Basic Information List
Table F. Hoffmann-La Roche Ltd. Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Orphan Drugs Sales Growth Rate (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Orphan Drugs Sales Market Share in United States (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Orphan Drugs Revenue Market Share in United States (2012-2017)
Table Pfizer, Inc. Basic Information List
Table Pfizer, Inc. Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pfizer, Inc. Orphan Drugs Sales Growth Rate (2012-2017)
Figure Pfizer, Inc. Orphan Drugs Sales Market Share in United States (2012-2017)
Figure Pfizer, Inc. Orphan Drugs Revenue Market Share in United States (2012-2017)
Table Sanofi S.A. Basic Information List
Table Sanofi S.A. Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sanofi S.A. Orphan Drugs Sales Growth Rate (2012-2017)
Figure Sanofi S.A. Orphan Drugs Sales Market Share in United States (2012-2017)
Figure Sanofi S.A. Orphan Drugs Revenue Market Share in United States (2012-2017)
Table Alexion Pharmaceuticals, Inc. Basic Information List
Table Alexion Pharmaceuticals, Inc. Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Alexion Pharmaceuticals, Inc. Orphan Drugs Sales Growth Rate (2012-2017)
Figure Alexion Pharmaceuticals, Inc. Orphan Drugs Sales Market Share in United States (2012-2017)
Figure Alexion Pharmaceuticals, Inc. Orphan Drugs Revenue Market Share in United States (2012-2017)
Table Eli Lilly and Company Basic Information List
Table Eli Lilly and Company Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Eli Lilly and Company Orphan Drugs Sales Growth Rate (2012-2017)
Figure Eli Lilly and Company Orphan Drugs Sales Market Share in United States (2012-2017)
Figure Eli Lilly and Company Orphan Drugs Revenue Market Share in United States (2012-2017)
Table Novo Nordisk A/S Basic Information List
Table Novo Nordisk A/S Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novo Nordisk A/S Orphan Drugs Sales Growth Rate (2012-2017)
Figure Novo Nordisk A/S Orphan Drugs Sales Market Share in United States (2012-2017)
Figure Novo Nordisk A/S Orphan Drugs Revenue Market Share in United States (2012-2017)
Table AstraZeneca Basic Information List
Table AstraZeneca Orphan Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure AstraZeneca Orphan Drugs Sales Growth Rate (2012-2017)
Figure AstraZeneca Orphan Drugs Sales Market Share in United States (2012-2017)
Figure AstraZeneca Orphan Drugs Revenue Market Share in United States (2012-2017)
Table Eisai Co., Ltd. Basic Information List
Table Daiichi Sankyo Company Limited Basic Information List
Table Bayer AG Basic Information List
Table GlaxoSmithKline Basic Information List
Table Merck & Co., Inc. Basic Information List
Table Johnson & Johnson Basic Information List
Table Biogen, Inc. Basic Information List
Table Shire Basic Information List
Table Amgen, Inc. Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Orphan Drugs
Figure Manufacturing Process Analysis of Orphan Drugs
Figure Orphan Drugs Industrial Chain Analysis
Table Raw Materials Sources of Orphan Drugs Major Players/Suppliers in 2016
Table Major Buyers of Orphan Drugs
Table Distributors/Traders List
Figure United States Orphan Drugs Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Orphan Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Orphan Drugs Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Orphan Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Orphan Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Orphan Drugs Sales Volume (K Units) Forecast by Type in 2022
Table United States Orphan Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Orphan Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Orphan Drugs Sales Volume (K Units) Forecast by Application in 2022
Table United States Orphan Drugs Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Orphan Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Orphan Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Orphan Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources